NasdaqGS - Nasdaq Real Time Price USD

REGENXBIO Inc. (RGNX)

9.79

+0.90

+(10.12%)

At close: May 19 at 4:00:00 PM EDT

9.65

-0.14

(-1.43%)

Pre-Market: 6:23:54 AM EDT

Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty

Regenxbio (RGNX) said Monday it closed a non-dilutive, limited recourse royalty bond agreement of up

PREMIUM
MT Newswires 13 hours ago

RGNX
+10.12%
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx). This agreement monetizes select anticipated royalties and milestones, and provides both immediate and expected future, non-dilutive capital. REGENXBIO received $150 million at closing, extending the Company's expected cash runway into early 2027.

PR Newswire 14 hours ago

RGNX
+10.12%
Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts

REGENXBIO Inc. ( NASDAQ:RGNX ) just released its latest first-quarter report and things are not looking great. It looks...

Simply Wall St. 5 days ago

RGNX
+10.12%
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) submission by REGENXBIO Inc. (REGENXBIO; Headquarters: Rockville, Maryland, USA; CEO: Curran M. Simpson, NASDAQ: RGNX) for RGX-121 (clemidsogene lanparvovec), a potential first-in-class, investigational gene therapy for the treatment of Mucopolysaccharidosis II (MPS II). The FDA granted

PR Newswire 5 days ago

RGNX
+10.12%
Q1 2025 Regenxbio Inc Earnings Call

Q1 2025 Regenxbio Inc Earnings Call

Thomson Reuters StreetEvents 6 days ago

RGNX
+10.12%

ABBV
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.

PR Newswire 6 days ago

RGNX
+10.12%
Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

Regenxbio Inc (RGNX) reports robust financial health and strategic advancements, with a focus on potential FDA approvals and commercial readiness.

GuruFocus.com 7 days ago

RGNX
+10.12%
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -70.73% and 19.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 days ago

RGNX
+10.12%
Regenxbio: Q1 Earnings Snapshot

ROCKVILLE, Md. AP) — Regenxbio Inc. RGNX) on Monday reported first-quarter earnings of $6.1 million.

Associated Press Finance 7 days ago

RGNX
+10.12%
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and recent operational highlights for the first quarter ended March 31, 2025.

PR Newswire 7 days ago

RGNX
+10.12%
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. The presentations highlight REGENXBIO's leading end-to-end capabilities across research and early development, late-stage clinical development, and gene therapy manufacturing.

PR Newswire 11 days ago

RGNX
+10.12%
REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

PR Newswire 13 days ago

RGNX
+10.12%
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 14 days ago

RGNX
+10.12%
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights.

PR Newswire 19 days ago

RGNX
+10.12%
Trump’s FDA Sends a Bullish Signal to Biotech

A vow by the agency’s new commissioner, Marty Makary, to support innovation might ease fears stoked by Health and Human Services Secretary Robert F. Kennedy Jr.

The Wall Street Journal 28 days ago

MFG

MZHOF

RGNX
+10.12%
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks last month

GLPG

GLPGF

PTCT
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old

The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain muscle integrity compared with control.

Clinical Trials Arena last month

RGNX
+10.12%

GLDAF
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated investigational gene therapy for Duchenne muscular dystrophy (Duchenne). Results were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

PR Newswire last month

RGNX
+10.12%
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner

We feel now is a pretty good time to analyse REGENXBIO Inc.'s ( NASDAQ:RGNX ) business as it appears the company may be...

Simply Wall St. 2 months ago

RGNX
+10.12%
Q4 2024 Regenxbio Inc Earnings Call

Q4 2024 Regenxbio Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

RGNX
+10.12%

ABBV

Performance Overview

Return	RGNX	S&P 500 (^GSPC)
YTD	+26.65%	+1.39%
1-Year	-38.77%	+12.45%
3-Year	-50.18%	+52.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

REGENXBIO Inc. (RGNX)

Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

Q1 2025 Regenxbio Inc Earnings Call

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

Regenxbio: Q1 Earnings Snapshot

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

REGENXBIO to Participate in Upcoming Investor Conferences

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Trump’s FDA Sends a Bullish Signal to Biotech

Biotech stocks slide as Marks resignation seen being negative for sector

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner

Q4 2024 Regenxbio Inc Earnings Call

Performance Overview